Skip to main content

Table 1 Demographic and clinical characteristics as a function of the HIV status of methadone patients from four hospitals (N = 576).

From: Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan

   HIV-positive HI- negative Total
   n = 71 (12%) n = 505 (88%)  
Age (years, mean ± SD) 39.3 ± 7.8 40.8 ± 9.4 40.6 ± 9.3
Age at first heroin use (years, mean ± SD) 25.9 ± 6.2 27.4 ± 7.5 27.2 ± 7.4
Gender Male Female 67 (90%) 7 (10%) 438 (87%) 64 (13%) 503 (87%) 73 (13%)
Source of treatment fee Self-paid 0 (0%) 330 (65.3%) 330 (57.3%)**
  Government sponsor 71 (100%) 175 (35.4%) 246 (42.7%)
Education Less than 9 years At least 9 years 22 (31%) 49 (69%) 142 (28%) 363 (72%) 164 (29%) 412 (71%)
Employed (n = 549)a No 30 (44%) 157 (33%) 187 (34%)
  Yes 38 (56%) 324 (67%) 362 (66%)
HCV (n = 552) a Negative 0 (0%) 38 (8%) 38 (7%)**
  Positive 66 (100%) 442 (92%) 514 (93%)
Morphine at intake (n = 545) a Negative 31 (45%) 145 (31%) 176 (32%)*
  Positive 38 (55%) 331 (69%) 369 (68%)
Morphine at interview (n = 506) a Negative 48 (76%) 294 (66%) 342 (68%)
  Positive 15 (24%) 149 (34%) 164 (32%)
Average methadone dose at intake (mg, mean ± SD) 37.5 ± 20.4 38.7 ± 20.3 38.5 ± 20.3
Average methadone dose at interview (mg, mean ± SD) 60.4 ± 35.0 48.2 ± 30.9 49.8 ± 31.7**
Time from intake to interview (days, mean ± SD) 218 ± 164 179 ± 146 184 ± 149*
  1. * p < 0.05.
  2. ** p < 0.01.
  3. a Missing values were omitted from the statistical analyses.
  4. Note: χ2 and t tests were used to examine differences between the HIV groups on categorical and continuous variables respectively. A Fisher exact test was performed to examine the relationship between HCV and HIV.